Pharmaron Biologics (UK) Ltd’s Post

It's always a challenge for a CDMO to identify and articulate what truly sets them apart from other similar businesses. In the case of Pharmaron's gene therapy CDMO services, one clear differentiator is the quality and breadth or our analytical services - from product release through to complex biophysical and physico-chemical characterisation techniques. Not to mention Angela herself! 😃 See for yourself in this clip!

Check out our latest show reel to learn more about Pharmaron’s comprehensive analytical support and how we can help you with your next gene therapy CMC project.

ELIQUENT Expert - Katie McKay - examines two new FDA guidance documents impacting Cell & Gene Therapy (CGT) products. Read Katie's analysis at https://lnkd.in/e_cqsnDG and learn more about ELIQUENT Life Sciences CGT capabilities at ELIQUENT.com

Overcoming manufacturing, delivery, and affordability challenges for cell and gene therapies in the Asia-Pacific region https://lnkd.in/efNFUyFj learnings from local case studies. In this update, we share two case studies that explore how local innovators in the cell and gene therapy space in Asia-Pacific are addressing some of the major challenges for access in the region. https://lnkd.in/efNFUyFj #MarketAccess #HEOR #WeAreAvalereHealth

Cell and gene therapies: the capabilities journey for Asia-Pacific players https://lnkd.in/enGMJFKE In the Asia-Pacific (APAC) region, there are five key milestones that are crucial for the success of players in the Cell and gene therapy (CGT) arena. This update summarizes some of the local players against these milestones. https://lnkd.in/enGMJFKE #MarketAccess #HEOR #WeAreAvalereHealth

📊 FREE REPORT SAMPLE: Preview The Cell and Gene Therapy Deals Analysis Report 🔬 Get A Sneak Peak Before You Invest! Find within the report Table of Contents, a sample chapter, and descriptions of the data, charts, tables, figures, and summaries offered in the full report! With more than1500 companies in the CGT space, understanding trends and the competitive landscape is crucial for strategic planning. Kalorama’s new report, The Cell and Gene Therapy Deals Analysis can help you identify key opportunities. These valuable insights are just a click away! 📥 DOWNLOAD THE FREE REPORT SAMPLE NOW: https://hubs.la/Q02CT9Yg0

The cell and gene therapy (CGT) sector is entering a new era. The path to commercialization of CGT products is complex and lined with challenges that can delay market entry and impact product success. Read our experts’ step-by-step guide to CGT commercialization: https://ow.ly/4lGR50QsKcF

The white paper titled, “Managing the Challenges of Paying for Gene Therapy: Strategies for Market Action and Policy Reform” has been co-developed by Institute for Clinical and Economic Review (ICER) and NEWDIGS Initiative at Tufts Medical Center to advance understanding around the complexities associated with the payment landscape for #genetherapies. Read our summary and a collection of initial reactions at The Evidence Base®. #genetherapy #valueassessment #healtheconomics #outcomesresearch #marketaccess #healthpolicy #rwe #realworldevidence #pharma #biopharma

Cell and gene therapy market access in the Asia-Pacific region https://lnkd.in/gDcefWnY This on-demand webinar delves into the cell and gene therapy (CGT) landscape in the Asia-Pacific (APAC) region. It examines market access dynamics for both global and local CGT products and uncovers the crucial factors that manufacturers need to consider to optimize CGT access in APAC. Watch the on-demand recording https://lnkd.in/gDcefWnY #MarketAccess #HEOR #WeAreAvalereHealth

Expand Your Biopharma and Gene Therapy Knowledge This glossary serves as a helpful reference to both novice and advanced scientists, researchers, and business executives involved with biopharmaceuticals and gene therapy technologies. Download eBook: https://bit.ly/4cu4UO5